Silence Therapeutics Plc - American Depository Share — Statistiche Finanziarie Trimestrali (NASDAQ:SLN)

Financials

Flusso di cassa derivante dalle attività operative -27.48 M-12.31 M-21.78 M-10.89 M-17.29 M -62.27 M Flussi di cassa derivanti dalle attività di investimento 66.13 M-44.38 M-1.56 M51.29 M-53.34 M -47.99 M Liquidità derivante dalle attività di finanziamento -98 K14 K1 00000 15 K Liquidità libera -27.54 M-12.31 M-21.83 M-10.89 M-17.29 M -62.33 M

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

SLN

Financials

Silence Therapeutics Plc - American Depository Share

Notizie

Gli EPS di Silence Therapeutics hanno battuto le aspettative per 0,11$, il fatturato appena sotto le previsioni

Silence Therapeutics earnings beat by $0.11, revenue fell short of estimates

Jefferies conferma Buy su Silence Therapeutics in attesa di dati

Jefferies reiterates Buy on Silence Therapeutics stock ahead of data

Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?

William Blair conferma il rating su Silence Therapeutics per il potenziale di divesiran

William Blair reiterates Silence Therapeutics stock rating on divesiran potential

H.C. Wainwright conferma il rating Buy su Silence Therapeutics a $75

H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75

Silence Therapeutics nomina il CFO Rhonda Hellums al consiglio di amministrazione

TreeFrog Therapeutics nomina Mark Rothera come nuovo CEO

TreeFrog Therapeutics appoints Mark Rothera as new CEO